Neuboron Medtech Ltd., based in China, has received clinical trial approval for its borofalan (10b) injection, as indicated on the website of China’s Center for Drug Evaluation (CDE). This marks the first boron neutron capture therapy (BNCT) to enter regulatory studies in China and the second globally, targeting recurrent malignant tumors of the head and neck.
The first BNCT drug, steboronine, was approved in Japan in March 2020 for the treatment of unresectable, locally advanced, or recurrent head and neck cancer. It has demonstrated strong therapeutic efficacy across numerous clinical studies for various cancers, including brain tumors, malignant melanoma, lung cancer, pleural mesothelioma, liver cancer, and breast cancer.
Neuboron’s borofalan is a broad-spectrum boron-containing drug that utilizes the L-type amino acid transporter system (LAT-1) for delivery.- Flcube.com
